

# CORONAVIRUS INFORMATION & UPDATES

May 7, 2020

## Supplemental Funding for Research – Key Civilian Agencies as of May 5, 2020

Agency	Coronavirus Preparedness and Response Supplemental Appropriations Act PL 116-123	Coronavirus Aid, Relief, and Economic Security Act (CARES Act) PL 116-136	Coronavirus Paycheck Protection and Health Care Enhancement Act PL 116-139	Total
HHS/NIH	<p>\$836 million available to the National Institute of Allergy and Infection Disease (NIAID) at NIH. The funds are for preparedness and response to COVID-19. NIAID supports scientific research on COVID-19 and other coronaviruses, as well as product development for medical countermeasures (e.g., vaccines) that could be used to curb the spread of the virus and/or to lessen its health impact. The bill specifies that of the total provided to NIAID, not less than \$10 million is to be transferred to the National Institute of Environmental Health Sciences (NIEHS) for worker-based training to prevent and reduce exposure of hospital employees, emergency first responders, and other workers who are at risk of exposure to coronavirus through their work duties. NIEHS is the primary NIH</p>	<p>\$945.5 million in total, distributed as follows:</p> <ul style="list-style-type: none"> <li>– \$706 million to the NIH-NIAID, provided that:                             <ul style="list-style-type: none"> <li>o \$156 million is used for the study of, construction of, demolition of, renovation of, and acquisition of equipment for vaccine and infectious disease research facilities of or used by the NIH (including the acquisition of real property).</li> </ul> </li> <li>– \$103.4 million to the NIH- National Heart, Lung, and Blood Institute (NHLBI).</li> <li>– \$60 million to the National Institute of Biomedical Imaging and Bioengineering (NIBIB).</li> <li>– \$36 million for the National Center for Advancing Translational Sciences (NCATS).</li> </ul>	<p>... to remain available until expended as follows:</p> <ul style="list-style-type: none"> <li>– \$306 million shall be transferred to the NIH – National Cancer Institute (NCI) to develop, validate, improve, and implement serological testing and associated technologies.</li> <li>– \$500 million shall be transferred to the NIH – National Institute of Biomedical Imaging and Bioengineering (NIBIB) to accelerate research, development, and implementation of point of care and other rapid</li> </ul>	<p><b>Est. \$3.6 billion</b></p>

# CORONAVIRUS INFORMATION & UPDATES



	<p>institute for environmental health research.</p>	<ul style="list-style-type: none"> <li>- \$30 million for the NIH Office of the Director (Common Fund).</li> <li>- \$10 million for the National Library of Medicine (NLM).</li> </ul>	<p>testing related to coronavirus. \$1 billion shall be transferred to the NIH – Office of the Director – to develop, validate, improve, and implement testing and associated technologies; to accelerate research, development, and implementation of point of care and other rapid testing; and for partnerships with governmental and non-governmental entities to research, develop, and implement the activities outlined in the Act.</p>	
<p>HHS/ASPR, including Biomedical Advanced Research and Development Authority (BARDA)</p>	<p>\$3.1 billion for domestic and international coronavirus and preparedness response, including:</p> <ul style="list-style-type: none"> <li>- Product development and manufacturing for medical countermeasures (vaccines, diagnostics, and therapeutics)</li> </ul>	<p>\$27 billion for developing countermeasures, vaccines, and other preparedness and response measures. This amount is divided, in relevant part, as follows:</p> <ul style="list-style-type: none"> <li>- \$3.5 billion is allocated to BARDA for the production and manufacture of vaccines and small molecules active ingredients, including to support</li> </ul>	<p>\$1 billion to BARDA for necessary expenses of advanced research, development, manufacturing, production, and purchase of diagnostic, serologic, or other COVID-19 tests or related supplies, and other activities related to COVID-19 testing at the discretion of the Secretary.</p>	<p><b>~1+ billion [allocation for research goods, and services not yet clear]</b></p>

# CORONAVIRUS INFORMATION & UPDATES

	<p>prioritizing platform-based technologies with U.S.-based manufacturing capabilities; and</p> <ul style="list-style-type: none"> <li>– The development of manufacturing platforms for such products;</li> </ul>	<p>early scaling-up of manufacturing capacity, at risk prior to new drug approval, or label expansion of existing medications addressing COVID-19.</p>		
National Science Foundation (NSF)	N/A	<p>\$75 million to the NSF for research to prevent, prepare for, and respond to coronavirus, domestically or internationally, including to fund research grants and other necessary expenses” (Rapid Response Research (RAPID) funding mechanism).</p>	N/A	<p><b>\$75 million</b></p>